ReviewStem cell research & therapy2020
Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia.
Review in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Journal of translational medicine · 2024Pooled it
- Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.Clinical and translational medicine · 2021Trial
- MSCs and MSC-Exos in pediatric ARDS treatment: translational research and the reshaping of nursing roles.Frontiers in pediatrics · 2026Review
- Beyond immunomodulation: mechanisms and synergistic strategies of mesenchymal stem cells in promoting alveolar epithelial and endothelial repair in ARDS.Frontiers in immunology · 2026Review
- Multifaceted mechanisms and targeted delivery of mesenchymal stem cell-derived exosomes in cardiovascular diseases: a translational medicine perspective.Frontiers in medicine · 2025Review
- The role of natural exosomes from SHED-MSC in immunoregulation of M0/M1 polarized macrophage cells.Frontiers in immunology · 2025Article
- The Main Mechanisms of Mesenchymal Stem Cell-Based Treatments against COVID-19.Tissue engineering and regenerative medicine · 2024Review
- Current Strategies and Therapeutic Applications of Mesenchymal Stem Cell-Based Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Role of Extracellular Vesicles in Metabolic Diseases.Biomedicines · 2024Review
- Mesenchymal Stem Cell-Derived Exosomes Attenuate Murine Cytomegalovirus-Infected Pneumonia via NF-κB/NLRP3 Signaling Pathway.Viruses · 2024Article
- Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic.American journal of stem cells · 2024Review
- Tumor-derived extracellular vesicles regulate macrophage polarization: role and therapeutic perspectives.Frontiers in immunology · 2024Article
- PLGA nanoparticles engineering extracellular vesicles from human umbilical cord mesenchymal stem cells ameliorates polyethylene particles induced periprosthetic osteolysis.Journal of nanobiotechnology · 2023Article
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS.International journal of molecular sciences · 2023Article
- Comparison of the therapeutic effects between stem cells and exosomes in primary ovarian insufficiency: as promising as cells but different persistency and dosage.Stem cell research & therapy · 2023Article
- Extracellular vesicles derived from mesenchymal stem cells - a novel therapeutic tool in infectious diseases.Inflammation and regeneration · 2023Review
- Immune Mechanisms of Pulmonary Fibrosis with Bleomycin.International journal of molecular sciences · 2023Review
- Extracellular vesicles in renal cell carcinoma: challenges and opportunities coexist.Frontiers in immunology · 2023Review
- Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.Stem cell research & therapy · 2022Review
- COVID-19 inflammation and implications in drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe outbreak of a new virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the main health concern all over the world. Since effective antiviral treatments have not been developed until now, SARS-CoV-2 is severely affecting countries and territories around the world.
methodsAt the present review, articles in PubMed were searched with the following terms: mesenchymal stem cells, exosomes, coronavirus, and SARS-CoV-2, either alone or in a combination form. The most relevant selected functions were mesenchymal stem cell-derived exosomes and SARS-CoV-2 virus infection.
resultsSARS-CoV-2 could damage pulmonary cells and induce secretion of different types of inflammatory cytokines. In the following, these cytokines trigger inflammation that damages the lungs and results in lethal acute respiratory distress syndrome (ARDS). The main characteristic of ARDS is the onset of inflammation in pulmonary, hyaline formation, pulmonary fibrosis, and edema. Mesenchymal stem cell-derived exosomes (MSC-Exo) are believed to have anti-inflammatory effects and immune-modulating capacity as well as the ability to induce tissue regeneration, suggesting a significant therapeutic opportunity that could be used to SARS-CoV-2 pneumonia treatment. Besides, exosomes may serve as a biomarker, drug delivery system, and vaccine for the management of the patient with SARS-CoV-2.
conclusionMSC-Exo may serve as a promising tool in the treatment of SARS-CoV-2 pneumonia. However, further work needs to be carried out to confirm the efficacy of exosomes in the treatment of SARS-CoV-2 pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.